Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Insect Nucleic Acid Residue Assay Kits based on quantitative fluorescence PCR technology. These kits are designed for highly sensitive and specific detection of insect DNA residues, ensuring the quality and safety
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced its comprehensive suite of Vaccine Evaluation Services to support researchers and pharmaceutical companies in the critical early stages of antiviral vaccine evaluation and development. These laboratory services provide guidance for early vaccine detection, ensure
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of its new range of BNP and NT-proBNP antibodies for raw material and research applications. These antibodies have been meticulously validated for use in ELISA, LFIA, CLIA, and Western blot. With excellent specificity
Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Bacterial DNA Residue Assay Kits (qPCR) for researchers to detect and quantify trace amounts of bacterial DNA contamination in a wide range of biopharmaceutical products, ensuring the highest standards of safety
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples, is excited to announce the release of its Cyclopiazonic Acid Test Reagents to help ensure food safety. These reagents are designed to support the
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is pleased to announce availability of its MERS-CoV Animal Models to support antiviral research. These animal models are valuable tools to advance research into the complex pathogenesis of MERS-CoV, evaluate potential therapeutic interventions and accelerate the
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, announces the launch of its new Ovalbumin Epitope Peptide Antibodies for immunological research by enabling precise and efficient analysis of immune responses. These antibodies can be applied in immunology, allergy, and vaccine development research. Ovalbumin (OVA), a
Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, is proud to announce the launch of its new Yeast DNA Residue Assay Kits (qPCR) for detecting and quantifying yeast DNA residues in various samples. These innovative assay kits offer researchers a highly sensitive and accurate method to
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples, is pleased to announce the launch of its new Zearalenone Test Reagents for accurate and reliable detection of Zearalenone, empowering researchers, food safety professionals,
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is excited to announce the launch of its new line of H5N1 Antibodies and Antigens to support cutting-edge research on this highly pathogenic influenza A virus subtype. These innovative products offer researchers and scientists invaluable tools for
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the launch of its Anti-Chimeric Antigen Receptor Linker Antibodies, including G4S linker antibodies and Whitlow 218 linker antibodies. These novel tools empower researchers to develop next-generation CAR T-cell therapies with a more efficient